Outpatient Treatment in Low-Risk Pulmonary Embolism Patients Receiving Direct Acting Oral Anticoagulants Is Associated With Cost Savings
(2020) In Clinical and Applied Thrombosis/Hemostasis 26.- Abstract
Direct oral anticoagulants (DOAC) are first line treatment for pulmonary embolism (PE). Treatment of acute PE is traditionally hospital based and associated with high costs. The aims of this study were to evaluate potential cost savings with outpatient DOAC treatment compared to inpatient DOAC treatment in patients with low risk PE. A retrospective study in patients with DOAC treated low risk PE (simplified pulmonary severity index [sPESI] ≤ 1) admitted to 8 hospitals during 2013-2015. Health care costs were compared in 223(44%) patients treated as outpatients and 287(56%) treated in hospital. Total cost per patient was 8293 EUR in the inpatient group, and 2176 EUR in the outpatient group (p < 0.001). Total costs for inpatients were... (More)
Direct oral anticoagulants (DOAC) are first line treatment for pulmonary embolism (PE). Treatment of acute PE is traditionally hospital based and associated with high costs. The aims of this study were to evaluate potential cost savings with outpatient DOAC treatment compared to inpatient DOAC treatment in patients with low risk PE. A retrospective study in patients with DOAC treated low risk PE (simplified pulmonary severity index [sPESI] ≤ 1) admitted to 8 hospitals during 2013-2015. Health care costs were compared in 223(44%) patients treated as outpatients and 287(56%) treated in hospital. Total cost per patient was 8293 EUR in the inpatient group, and 2176 EUR in the outpatient group (p < 0.001). Total costs for inpatients were higher (p < 0.001) compared to outpatients in both subgroups with sPESI 0 and 1. In multivariate analysis, type of treatment (in- or outpatient, p = < 0.001) and sPESI group (0 or 1, p = < 0.001) were associated with total cost below or above median, whereas age (p = 0.565) and gender (p = 0.177) was not. Adherence to guidelines recommending outpatient treatment with DOAC in patients with low risk PE enables significant savings.
(Less)
- author
- Ghazvinian, Raein LU ; Elf, Johan LU ; Löfvendahl, Sofia LU ; Holst, Jan LU and Gottsäter, Anders LU
- organization
- publishing date
- 2020
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- cost savings, direct oral anticoagulant, inpatient, outpatient, pulmonary embolism, venous thromboembolism
- in
- Clinical and Applied Thrombosis/Hemostasis
- volume
- 26
- publisher
- SAGE Publications
- external identifiers
-
- scopus:85097029950
- pmid:33259227
- ISSN
- 1076-0296
- DOI
- 10.1177/1076029620937352
- language
- English
- LU publication?
- yes
- id
- e65a5a63-e2bb-48cf-b8a6-79337c700f27
- date added to LUP
- 2020-12-11 12:55:20
- date last changed
- 2024-10-03 14:29:29
@article{e65a5a63-e2bb-48cf-b8a6-79337c700f27, abstract = {{<p>Direct oral anticoagulants (DOAC) are first line treatment for pulmonary embolism (PE). Treatment of acute PE is traditionally hospital based and associated with high costs. The aims of this study were to evaluate potential cost savings with outpatient DOAC treatment compared to inpatient DOAC treatment in patients with low risk PE. A retrospective study in patients with DOAC treated low risk PE (simplified pulmonary severity index [sPESI] ≤ 1) admitted to 8 hospitals during 2013-2015. Health care costs were compared in 223(44%) patients treated as outpatients and 287(56%) treated in hospital. Total cost per patient was 8293 EUR in the inpatient group, and 2176 EUR in the outpatient group (p < 0.001). Total costs for inpatients were higher (p < 0.001) compared to outpatients in both subgroups with sPESI 0 and 1. In multivariate analysis, type of treatment (in- or outpatient, p = < 0.001) and sPESI group (0 or 1, p = < 0.001) were associated with total cost below or above median, whereas age (p = 0.565) and gender (p = 0.177) was not. Adherence to guidelines recommending outpatient treatment with DOAC in patients with low risk PE enables significant savings.</p>}}, author = {{Ghazvinian, Raein and Elf, Johan and Löfvendahl, Sofia and Holst, Jan and Gottsäter, Anders}}, issn = {{1076-0296}}, keywords = {{cost savings; direct oral anticoagulant; inpatient; outpatient; pulmonary embolism; venous thromboembolism}}, language = {{eng}}, publisher = {{SAGE Publications}}, series = {{Clinical and Applied Thrombosis/Hemostasis}}, title = {{Outpatient Treatment in Low-Risk Pulmonary Embolism Patients Receiving Direct Acting Oral Anticoagulants Is Associated With Cost Savings}}, url = {{http://dx.doi.org/10.1177/1076029620937352}}, doi = {{10.1177/1076029620937352}}, volume = {{26}}, year = {{2020}}, }